An Open-label, Multi-center, Single-arm, Phase IV Clinical Trial Assessing Conversion From Hydrocodone, Oxycodone CR or Morphine SR to Tapentadol ER in Subjects With Moderate to Severe Chronic Low Back or OA Pain of the Hip or Knee
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain; Osteoarthritis; Pain
- Focus Therapeutic Use
- Sponsors Janssen
- 25 Jan 2018 Status changed from discontinued to withdrawn prior to enrolment.
- 26 Dec 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 07 Sep 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.